This is not the most recent version of the article. View current version (19 FEB 2015)

Intervention Review

You have free access to this content

Primaquine for reducing Plasmodium falciparum transmission

  1. Patricia M Graves1,2,*,
  2. Hellen Gelband3,
  3. Paul Garner4

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 12 SEP 2012

Assessed as up-to-date: 5 JUL 2012

DOI: 10.1002/14651858.CD008152.pub2


How to Cite

Graves PM, Gelband H, Garner P. Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD008152. DOI: 10.1002/14651858.CD008152.pub2.

Author Information

  1. 1

    EpiVec Consulting, Atlanta, USA

  2. 2

    James Cook University, School of Public Health, Tropical Medicine and Rehabilitation Sciences, Cairns, Queensland, Australia

  3. 3

    Center for Disease Dynamics, Economics & Policy, Washington, DC, USA

  4. 4

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

*Patricia M Graves, School of Public Health, Tropical Medicine and Rehabilitation Sciences, James Cook University, PO Box 6811, Cairns, Queensland, 4870, Australia. pgraves.work@gmail.com. patricia.graves@jcu.edu.au.

Publication History

  1. Publication Status: New
  2. Published Online: 12 SEP 2012

SEARCH

This is not the most recent version of the article. View current version (19 FEB 2015)

[Figure 1]
Figure 1.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 4]
Figure 4. Study flow diagram.
[Analysis 1.1]
Analysis 1.1. Comparison 1 GIVEN WITH CQ, OR CQ+SP, Outcome 1 Participants with gametocytes.
[Analysis 1.2]
Analysis 1.2. Comparison 1 GIVEN WITH CQ, OR CQ+SP, Outcome 2 Participants with asexual parasites (treatment failure day 29).
[Analysis 2.1]
Analysis 2.1. Comparison 2 GIVEN WITH SP, Outcome 1 Participants with gametocytes.
[Analysis 2.2]
Analysis 2.2. Comparison 2 GIVEN WITH SP, Outcome 2 Participants with asexual parasites (treatment failure day 29).
[Analysis 3.1]
Analysis 3.1. Comparison 3 GIVEN WITH MQ, OR MQ+SP, Outcome 1 Participants infectious.
[Analysis 3.2]
Analysis 3.2. Comparison 3 GIVEN WITH MQ, OR MQ+SP, Outcome 2 Mosquitoes infected.
[Analysis 3.3]
Analysis 3.3. Comparison 3 GIVEN WITH MQ, OR MQ+SP, Outcome 3 Gametocyte clearance time (days).
[Analysis 3.4]
Analysis 3.4. Comparison 3 GIVEN WITH MQ, OR MQ+SP, Outcome 4 Asexual parasite clearance time (hrs).
[Analysis 4.1]
Analysis 4.1. Comparison 4 GIVEN WITH QN, Outcome 1 Participants with gametocytes.
[Analysis 4.2]
Analysis 4.2. Comparison 4 GIVEN WITH QN, Outcome 2 Asexual parasite clearance time (hours).
[Analysis 5.1]
Analysis 5.1. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 1 Participants with gametocytes (microscopy).
[Analysis 5.2]
Analysis 5.2. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 2 Participants with gametocytes (PCR).
[Analysis 5.3]
Analysis 5.3. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 3 Log(10) AUC of gametocyte density over time d1-43.
[Analysis 5.4]
Analysis 5.4. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 4 Participants with asexual parasites (PCR).
[Analysis 5.5]
Analysis 5.5. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 5 Asexual parasite clearance time.
[Analysis 5.6]
Analysis 5.6. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 6 Haemoglobin concentration.
[Analysis 5.7]
Analysis 5.7. Comparison 5 GIVEN WITH AS, OR WITH ACTs, Outcome 7 % change in haemoglobin concentration.
[Analysis 6.1]
Analysis 6.1. Comparison 6 ALL TREATMENTS COMBINED, Outcome 1 Participants with gametocytes at day 8 (microscopy).